# TerSera Therapeutics

> TerSera Therapeutics is a privately held biopharmaceutical company based in Deerfield, Illinois, focused on acquiring, developing, and commercializing specialty medicines in oncology, rare disease, and non-opioid pain. Launched in 2016 with backing from private equity firm GTCR, TerSera builds its portfolio through targeted acquisitions of approved and late-stage assets, including ZOLADEX, XERMELO, PRIALT, and VARUBI, with a stated mission of building 'the new cornerstones of care' for patients with limited treatment options.

- **Founded:** 2016
- **Headquarters:** Deerfield, Illinois, United States
- **Founders:** Edward J. Fiorentino (Co-Founder & Executive Chairman (former CEO))
- **Team size:** ~220 employees
- **Products:** ZOLADEX (goserelin), XERMELO (telotristat ethyl), PRIALT (ziconotide), VARUBI (rolapitant), Quzyttir (cetirizine injection)
- **Notable:** Built a multi-product specialty pharma portfolio in under a decade through targeted acquisitions, Commercializes XERMELO, the first and only approved oral therapy for carcinoid syndrome diarrhea, Maintained PRIALT, the only FDA-approved non-opioid intrathecal pain therapy, on the U.S. market

## Products & services

- **ZOLADEX (goserelin)** — Hormone-based therapy used in oncology; acquired from AstraZeneca in TerSera's first product deal.
- **XERMELO (telotristat ethyl)** — First and only FDA-approved oral therapy for carcinoid syndrome diarrhea caused by metastatic neuroendocrine tumors, used with somatostatin analog therapy.
- **PRIALT (ziconotide)** — Only FDA-approved non-opioid intrathecal infusion treatment for severe chronic pain; divested to ESTEVE in 2026 as part of the Infusion Specialty Therapies unit.
- **VARUBI (rolapitant)** — Antiemetic used to help prevent chemotherapy-induced nausea and vomiting, part of the oncology franchise.
- **Quzyttir (cetirizine injection)** — Injectable antihistamine, part of the Infusion Specialty Therapies business divested to ESTEVE in 2026.

## Achievements

- Built a multi-product specialty pharma portfolio in under a decade through targeted acquisitions
- Commercializes XERMELO, the first and only approved oral therapy for carcinoid syndrome diarrhea
- Maintained PRIALT, the only FDA-approved non-opioid intrathecal pain therapy, on the U.S. market
- Completed its first product acquisition (ZOLADEX) from AstraZeneca in 2016
- Executed a strategic 2026 divestiture to ESTEVE to refocus on oncology and rare disease

## Latest updates

- **2026-01** — ESTEVE agreed to acquire TerSera's Infusion Specialty Therapies business unit (including PRIALT and Quzyttir), expanding ESTEVE's U.S. presence and letting TerSera refocus on oncology and rare disease.
- **2025-01** — TerSera presented real-world data on intrathecal ziconotide (PRIALT) prescription patterns at ASPN 2025.
- **2024-01** — Updated 2024 Polyanalgesic Consensus Conference (PACC) guidelines issued new guidance relevant to administering PRIALT.

## Links

- Website: https://tersera.com
- LinkedIn: https://www.linkedin.com/company/tersera
- Facebook: https://www.facebook.com/TerSera

---

Profile page: https://yespress.io/tersera-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-07-03